Arrowstreet Capital’s Kyntra Bio KYNB Stock Holding History

Arrowstreet Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,624	Closed	-$1.88M	–	1151
2018 Q1	$1.88M	Buy	1,624 +1,000	+160%	+$1.32M	﹤0.01%	757
2017 Q4	$739K	Buy	+624	New	+$782K	﹤0.01%	1014
2015 Q4	–	Sell	-2,331	Closed	-$1.28M	–	1469
2015 Q3	$1.28M	Buy	2,331 +243	+12%	+$147K	0.01%	857
2015 Q2	$1.23M	Buy	+2,088	New	+$1.21M	0.01%	768

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Arrowstreet Capital's KYNB Position: Q2 2018 in Review

Arrowstreet Capital sold out of Kyntra Bio (KYNB) in Q2 2018, closing a stake of 1,624 shares — an estimated $1.88M sold.

Arrowstreet Capital first reported a position in KYNB in Q2 2015 and held it in 4 quarters. The position peaked at $1.88M in Q1 2018. 192 funds tracked by Wall St. Rank hold KYNB as of Q2 2018.

Arrowstreet Capital reported no remaining Kyntra Bio position as of Q2 2018 after selling out during the quarter.
Arrowstreet Capital sold 1,624 Kyntra Bio shares in Q2 2018, an estimated $1.88M.
Arrowstreet Capital first reported a position in Kyntra Bio in Q2 2015 and held it in 4 quarters.
Arrowstreet Capital's Kyntra Bio position peaked at $1.88M in Q1 2018.
192 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2018.

Based on Arrowstreet Capital's 13F filing for Q2 2018, filed 14 Aug 2018.